By analysis of samples from human benign nevi, primary melanoma, and melanoma metastases in comparison with normal skin, the study of Ulrike Leiter and colleagues demonstrated that Bcl-xL was expressed in all metastatic melanoma samples, 80% of nevi and 62% of normal tissue samples, illustrating how Bcl-xL increases its expression passing from primary to metastatic melanoma [97]. This evidence concerns the gene BCL2L1 and melanoma.